Our Pricing

How to Safely Switch from Mounjaro to Wegovy in the UK

Swapping Mounjaro to Wegovy is becoming increasingly common among UK patients seeking alternative GLP-1 receptor agonist therapy for weight management. Whether you're considering the switch due to supply issues, cost considerations, or clinical response, understanding the dose equivalence and transition protocol is essential for maintaining your weight loss progress. At Cured Pharmacy, our UK-registered clinical team provides expert guidance on safely transitioning between tirzepatide and semaglutide under proper prescriber supervision.

Understanding the Difference When Swapping Mounjaro to Wegovy

When swapping Mounjaro to Wegovy, you're transitioning from tirzepatide (a dual GIP/GLP-1 receptor agonist) to semaglutide (a selective GLP-1 receptor agonist). Both medications are licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Clinical trials demonstrate that tirzepatide may produce slightly greater average weight loss than semaglutide, with SURPASS-2 showing up to 15% body weight reduction with Mounjaro 15mg compared to approximately 12-15% with Wegovy 2.4mg in STEP trials [2].

The mechanism difference is clinically significant: Mounjaro's dual action on both GIP and GLP-1 receptors may offer enhanced glycaemic control and appetite suppression, while Wegovy's selective GLP-1 action has extensive cardiovascular outcome data. Many patients switching from Mounjaro to Wegovy maintain effective weight loss, though individual response varies. The transition requires careful dose mapping to minimise side effects and preserve therapeutic benefit, which our UK prescribers assess during your clinical consultation.

Clinical Efficacy Comparison

Direct head-to-head trials comparing tirzepatide and semaglutide show both medications deliver clinically meaningful weight reduction. In the SURPASS-2 trial, tirzepatide 15mg demonstrated superior weight loss compared to semaglutide 1mg (the diabetes dose, not the weight loss dose), though real-world comparisons at maximum weight loss doses show more comparable results [3]. Patients swapping Mounjaro to Wegovy typically experience continued weight loss or weight maintenance when proper dose equivalence is observed and lifestyle modifications continue.

Dose Conversion Guide for Swapping Mounjaro to Wegovy

There is no officially established dose equivalence for swapping Mounjaro to Wegovy, as the medications work through different receptor mechanisms. However, UK prescribers typically use clinical judgement based on your current Mounjaro dose, treatment duration, and individual response. A common approach involves transitioning to Wegovy's titration schedule from an appropriate starting point rather than attempting direct dose-for-dose conversion [4].

If you're currently on Mounjaro 2.5mg, your prescriber may recommend starting Wegovy at the standard 0.25mg dose and following the full titration schedule. For patients on higher Mounjaro doses (10mg or 15mg), some clinicians may consider starting Wegovy at 0.5mg or 1mg to reduce the risk of treatment gap, though this is individualised. The key principle when swapping Mounjaro to Wegovy is maintaining therapeutic continuity whilst allowing your body to adjust to the different receptor activity profile.

Step-by-Step Protocol for Swapping Mounjaro to Wegovy Safely

The safest approach to swapping Mounjaro to Wegovy involves consultation with a UK prescriber who can assess your individual circumstances. At Cured Pharmacy, our clinical team reviews your current dose, weight loss progress, side effect profile, and treatment goals before recommending a transition protocol. Most patients can switch directly without a washout period, administering the first Wegovy dose on the day the next Mounjaro dose would have been due [5].

During the transition, monitoring for gastrointestinal side effects is essential, as nausea, vomiting, and diarrhoea may occur even if you tolerated Mounjaro well. These effects are typically mild to moderate and diminish over 2-4 weeks as your body adapts. Your prescriber may recommend starting at a lower Wegovy dose than your Mounjaro dose equivalent to minimise side effects, then titrating upward every four weeks according to the licensed schedule. Maintaining consistent injection timing, proper hydration, and gradual meal portions supports a smoother transition.

Timeline and Titration Expectations

The standard Wegovy titration schedule begins at 0.25mg weekly for four weeks, increasing to 0.5mg, then 1mg, 1.7mg, and finally 2.4mg maintenance dose over approximately 16-20 weeks. When swapping Mounjaro to Wegovy, your prescriber may modify this timeline based on your previous dose. Patients transitioning from higher Mounjaro doses may reach the Wegovy maintenance dose faster, whilst those on lower doses typically follow the standard schedule to optimise tolerability and efficacy.

Cost Considerations When Swapping Mounjaro to Wegovy in the UK

One of the primary reasons UK patients consider swapping Mounjaro to Wegovy is cost difference. At Cured Pharmacy, Wegovy is available from £124.99 per month, compared to Mounjaro at £124.99 per month, representing significant savings over a typical 12-month treatment course. Both medications require prescription from a UK-registered prescriber following clinical assessment, and prices include the medication, prescriber consultation, and discreet home delivery.

When comparing the cost of swapping Mounjaro to Wegovy, consider the full treatment journey. Wegovy's lower monthly price may offset any temporary reduction in weight loss velocity during the transition period. New patients at Cured Pharmacy can save an additional £20 off their first order using code Weightlossnew, making Wegovy an economically attractive option for long-term weight management. Our transparent upfront pricing ensures you know the exact cost before completing your clinical assessment.

Managing Side Effects During the Transition from Mounjaro to Wegovy

Even if you experienced minimal side effects on Mounjaro, swapping Mounjaro to Wegovy may temporarily increase gastrointestinal symptoms due to the change in receptor activity. The most common side effects include nausea (reported in up to 44% of Wegovy users in STEP trials), diarrhoea, constipation, and abdominal discomfort [6]. These effects are typically most pronounced during dose escalation and often resolve within 4-8 weeks as tolerance develops.

To minimise side effects when swapping Mounjaro to Wegovy, eat smaller, more frequent meals, avoid high-fat foods immediately after injection, and stay well-hydrated. Injecting Wegovy on the same day each week, preferably in the evening after a light meal, may reduce nausea. If side effects become severe or persistent, contact your prescriber immediately — they may recommend slowing the titration schedule or providing symptomatic management strategies. Serious side effects such as severe abdominal pain, persistent vomiting, or signs of pancreatitis require urgent medical attention.

When to Contact Your Prescriber

While most patients tolerate swapping Mounjaro to Wegovy well, certain symptoms warrant prescriber contact. Seek advice if you experience severe or worsening nausea lasting beyond two weeks, inability to keep down fluids, signs of dehydration, severe abdominal pain, changes in vision, or unexplained persistent fatigue. Your Cured Pharmacy clinical team is available to review your progress and adjust your treatment plan as needed throughout the transition period.

Maintaining Weight Loss Results After Swapping Mounjaro to Wegovy

Clinical evidence suggests that patients swapping Mounjaro to Wegovy can maintain their weight loss achievements with proper dose optimisation and continued lifestyle modification. Both medications work by reducing appetite, slowing gastric emptying, and improving satiety signalling, though the dual receptor action of tirzepatide may produce slightly greater average results in some patients [7]. The key to sustained success lies in viewing the medication switch as part of a comprehensive weight management programme rather than a standalone intervention.

During the transition period, some patients experience a temporary plateau in weight loss as their body adjusts to semaglutide's mechanism. This is normal and typically resolves once the maintenance Wegovy dose (2.4mg) is achieved. Continue your established exercise routine, maintain a calorie-controlled diet rich in protein and fibre, and track your progress through regular weigh-ins. Our UK clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey, with follow-up consultations available to optimise your dosing and address any concerns when swapping Mounjaro to Wegovy.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2022). Public Assessment Report: Tirzepatide and semaglutide for weight management. MHRA. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance. NICE. [accessed 15 August 2026]
5. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
6. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
7. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.